Oncology
Zenocutuzumab-zbco (Bizengri; Merus N.V.) has been granted accelerated approval for adults with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy or advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC) harboring an NRG1 gene fusion with disease progression on or after prior systemic therapy. Read More ›
On December 13, 2024, FDA officials approved cosibelimab-ipdl (Unloxcyt; Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) blocking antibody, for adults with locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation or metastatic cutaneous squamous cell carcinoma (mCSCC). Read More ›
Patients diagnosed with major diseases, including cancer, often experience financial hardship due to high out-of-pocket medical costs in the United States. Read More ›
Increased access to broadband usage was associated with earlier-stage non-small cell lung cancer (NSCLC) diagnosis and with receiving guideline-concordant care in 2020, during the height of the COVID-19 pandemic. Read More ›
Pancreatic cancer is a devastating diagnosis, with a high mortality rate and few effective treatment options. For many veterans, the risk of developing pancreatic cancer may be linked to exposure to Agent Orange, a chemical herbicide widely used during the Vietnam War. Read More ›
There is a link between toxic exposures during military service and the prevalence of lung cancer among veterans, according to a study presented at the International Association for the Study of Lung Cancer (IASLC)’s 2024 World Conference on Lung Cancer, held recently in San Diego, California. Read More ›
People are generally more positive about the perception and frequency of biomarker testing than an earlier survey conducted in 2018, but barriers remain, according to results from a recently released survey. Read More ›
In the course of carrying out their duties, US military personnel face numerous hazards. Although the risks of combat are widely recognized, there are other lesser-known dangers that can have significant, long-lasting impacts on the health of those who serve in the military. Read More ›
The Department of Veterans Affairs (VA) announced in September that it will conduct a scientific assessment to determine if there is a relationship between per- and polyfluoroalkyl substances (PFAS) exposure during military service and kidney cancer among veterans. Read More ›